Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395799 | 1.00 | ACE (0.51) | ACELMNACTSKABCB11MEN1 | |
| SCHEMBL4395801 | 1.00 | ACE (0.51) | ACELMNACTSKABCB11MEN1 | |
| SCHEMBL9773242 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL7342910 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL7342915 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL9257644 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL9773173 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL10829372 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL9773168 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL7343890 | 0.92 | ACE (0.57) | ACELMNAABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675827-B1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | SERVIER LAB (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7456296-B2 | Method for preparation of crystalline perindopril erbumine | LUPIN LTD (IN) | 2008-11-25 | — | — | US | disclosed |
| EP-1603558-B1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | SERVIER S A LAB (FR) | 2008-05-21 | — | — | EP | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
| US-20060276659-A1 | Process for preparation of perindopril and salts thereof | LIPIN LIMITED (IN) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276659-A1 | Process for preparation of perindopril and salts thereof | CYP2C9, DPYD, CYP2C8 | ACE 10/4885LMNA 806/4885CTSK 1362/4885 |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | ACE 8/4885LMNA 1430/4885CTSK 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.